8-K - Pliant Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Pliant Therapeutics entered a new $50.0 million ATM sales agreement with Leerink Partners and terminated its prior 2021 sales agreement with Cantor Fitzgerald without penalties.

Key Takeaways

1Company entered a 2026 Sales Agreement with Leerink Partners LLC for an at-the-market offering program.

2The new ATM program allows for the sale of common stock with an aggregate offering price of up to $50.0 million.

3The Company terminated the 2021 Sales Agreement with Cantor Fitzgerald & Co. effective March 27, 2026.

4No termination penalties were incurred, and no shares were sold under the terminated 2021 agreement.

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events As previously disclosed, on March 30, 2026, Pliant Therapeutics, Inc. (the “Company”) entered into a Sales Agreement, or the 2026 Sales Agreement,

Other Event

$50.0M

Transaction Details

Material Agreement

Agreement: 2026 Sales Agreement
Parties: Pliant Therapeutics, Inc., Leerink Partners LLC

•At-the-market offering program to sell shares of common stock
•Aggregate offering price of up to $50.0 million
•Leerink Partners LLC acting as sales agent

Exhibits (1)

8-K